Jacobs Levy Equity Management, Inc Eiger Bio Pharmaceuticals, Inc. Transaction History

Jacobs Levy Equity Management, Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$6.68 - $9.1 $400,853 - $546,072	-60,008 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$7.82 - $9.23 $834,534 - $985,007	-106,718 Reduced 64.01%	60,008 $511,000
Q1 2021 May 17, 2021	SELL	$8.44 - $12.66 $311,587 - $467,381	-36,918 Reduced 18.13%	166,726 $1.48 Million
Q4 2020 Feb 16, 2021	SELL	$7.98 - $12.29 $694,690 - $1.07 Million	-87,054 Reduced 29.95%	203,644 $2.5 Million
Q3 2020 Nov 16, 2020	BUY	$7.96 - $12.42 $856,320 - $1.34 Million	107,578 Added 58.75%	290,698 $2.37 Million

Q2 2020 Aug 17, 2020	BUY	$5.4 - $13.37 $535,361 - $1.33 Million	99,141 Added 118.05%	183,120 $1.76 Million
Q1 2020 May 15, 2020	BUY	$4.91 - $14.7 $307,459 - $920,499	62,619 Added 293.16%	83,979 $571,000
Q4 2019 Feb 14, 2020	SELL	$9.77 - $15.66 $2,931 - $4,698	-300 Reduced 1.39%	21,360 $318,000
Q3 2019 Nov 14, 2019	BUY	$9.59 - $12.0 $207,719 - $259,920	21,660 New	21,660 $222,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $496M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.